The effect of age and quality of life on doctors' decisions to anticoagulate patients with atrial fibrillation

被引:8
作者
Sudlow, M [1 ]
Thomson, R
Rodgers, H
Livingstone, S
Kenny, RA
机构
[1] Newcastle Univ, Sch Med, Dept Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
[2] Newcastle Univ, Sch Med, Dept Epidemiol & Publ Hlth, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
关键词
age factors; anticoagulants; atrial fibrillation; cerebral embolism and thrombosis; cerebrovascular disorders; physicians practice patters; quality of life; warfarin;
D O I
10.1093/ageing/27.3.285
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Introduction: we report the results of a questionnaire survey into the effect of patients' age and of medico-social factors on hospital consultants' and general practitioners' reported use of warfarin anticoagulation to treat patients with non-valvular atrial fibrillation (NVAF). Methods: half of the general practitioners (n = 824) and all consultants in specialities likely to be involved in treating such patients (n = 207) in the former Northern Region were sent questionnaires asking for their views on the treatment of patients with atrial fibrillation using anticoagulants. Results: the response rate was 56% (459/824) for general practitioners and 76% (163/207) for consultants. A patient's age was of significance to many clinicians. Forty-six percent of consultants and 43% of general practitioners felt that no patient above the age of 84 years should be treated. Medico-social factors also had an important effect on whether clinicians felt patients ought to be treated with anticoagulants. ii patient's quality of life was the most important medico-social factor, with handicap and place of residence having much smaller effects. Conclusions: age and medico-social factors have an important effect on clinicians use of anticoagulants in NVAF and reluctance to treat elderly subjects is likely to explain much of the apparent under-use of this treatment.
引用
收藏
页码:285 / 289
页数:5
相关论文
共 23 条
[11]   ANTICOAGULANT-RELATED BLEEDING - CLINICAL EPIDEMIOLOGY, PREDICTION, AND PREVENTION [J].
LANDEFELD, CS ;
BEYTH, RJ .
AMERICAN JOURNAL OF MEDICINE, 1993, 95 (03) :315-328
[12]   ANTITHROMBOTIC THERAPY IN ATRIAL-FIBRILLATION [J].
LAUPACIS, A ;
ALBERS, G ;
DALEN, J ;
DUNN, M ;
FEINBERG, W ;
JACOBSON, A .
CHEST, 1995, 108 (04) :S352-S359
[13]  
LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449
[14]  
LIP GYH, 1994, BRIT HEART J, V71, P92
[15]   STROKE PREVENTION IN ATRIAL-FIBRILLATION STUDY - FINAL RESULTS [J].
MCBRIDE, R .
CIRCULATION, 1991, 84 (02) :527-539
[16]   Atrial fibrillation and stroke prevention in the community [J].
OConnell, JE ;
Gray, CS .
AGE AND AGEING, 1996, 25 (04) :307-309
[17]  
PETERSEN P, 1989, LANCET, V1, P175
[18]   PROTHROMBIN TIME RATIO AND OTHER FACTORS ASSOCIATED WITH BLEEDING IN PATIENTS TREATED WITH WARFARIN [J].
PETITTI, DB ;
STROM, BL ;
MELMON, KL .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1989, 42 (08) :759-764
[19]   IN DEFENSE OF AGEISM [J].
SHAW, AB .
JOURNAL OF MEDICAL ETHICS, 1994, 20 (03) :188-191
[20]   SERVICE PROVISION AND USE OF ANTICOAGULANTS IN ATRIAL-FIBRILLATION [J].
SUDLOW, CM ;
RODGERS, H ;
KENNY, RA ;
THOMSON, RG .
BRITISH MEDICAL JOURNAL, 1995, 311 (7004) :558-560